CliffBio
small molecule

AMBIEN CR

ZOLPIDEM TARTRATE

Loss of exclusivity—loss of exclusivity
CompanyCosette Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameAMBIEN CR
Active ingredientZOLPIDEM TARTRATE
Strength6.25MG
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalSeptember 2005
Marketing statusRX

More from Cosette Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.